RT @MeralElRamahiMD: #EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been mu

#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead! @RheumNow https://t.co/E61yb97CRN